WO2006061418A3 - Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus - Google Patents
Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus Download PDFInfo
- Publication number
- WO2006061418A3 WO2006061418A3 PCT/EP2005/056610 EP2005056610W WO2006061418A3 WO 2006061418 A3 WO2006061418 A3 WO 2006061418A3 EP 2005056610 W EP2005056610 W EP 2005056610W WO 2006061418 A3 WO2006061418 A3 WO 2006061418A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- hypersecretion
- agr2
- mucus
- agents useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05816225A EP1831367A2 (fr) | 2004-12-09 | 2005-12-08 | Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63458704P | 2004-12-09 | 2004-12-09 | |
US60/634,587 | 2004-12-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006061418A2 WO2006061418A2 (fr) | 2006-06-15 |
WO2006061418A3 true WO2006061418A3 (fr) | 2006-08-03 |
Family
ID=36297388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/056610 WO2006061418A2 (fr) | 2004-12-09 | 2005-12-08 | Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1831367A2 (fr) |
WO (1) | WO2006061418A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9415088B2 (en) | 2011-02-25 | 2016-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Use of AGR3 for treating cancer |
WO2021142245A1 (fr) * | 2020-01-10 | 2021-07-15 | Translate Bio, Inc. | Composés, compositions pharmaceutiques et méthodes pour moduler l'expression de la muc5b dans des cellules et des tissus pulmonaires |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041627A1 (fr) * | 1997-03-19 | 1998-09-24 | Zymogenetics, Inc. | Polypeptides secretes presentant une homologie avec les proteines de la glande cementaire du xenopus |
WO2002010449A2 (fr) * | 2000-07-28 | 2002-02-07 | Compugen Inc. | Bibliotheque d'oligonucleotides destinee a detecter des transcrits d'arn et des variantes d'epissure qui garnissent un transcriptome |
WO2004031239A2 (fr) * | 2002-10-02 | 2004-04-15 | The University Of Liverpool | Composes inducteurs de metastases |
WO2004056858A2 (fr) * | 2002-12-23 | 2004-07-08 | Ingenium Pharmaceuticals Ag | Methodes et agents pour le diagnostic et la prevention, l'amelioration ou le traitement de troubles lies aux cellules caliciformes |
-
2005
- 2005-12-08 EP EP05816225A patent/EP1831367A2/fr not_active Withdrawn
- 2005-12-08 WO PCT/EP2005/056610 patent/WO2006061418A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041627A1 (fr) * | 1997-03-19 | 1998-09-24 | Zymogenetics, Inc. | Polypeptides secretes presentant une homologie avec les proteines de la glande cementaire du xenopus |
WO2002010449A2 (fr) * | 2000-07-28 | 2002-02-07 | Compugen Inc. | Bibliotheque d'oligonucleotides destinee a detecter des transcrits d'arn et des variantes d'epissure qui garnissent un transcriptome |
WO2004031239A2 (fr) * | 2002-10-02 | 2004-04-15 | The University Of Liverpool | Composes inducteurs de metastases |
WO2004056858A2 (fr) * | 2002-12-23 | 2004-07-08 | Ingenium Pharmaceuticals Ag | Methodes et agents pour le diagnostic et la prevention, l'amelioration ou le traitement de troubles lies aux cellules caliciformes |
Also Published As
Publication number | Publication date |
---|---|
EP1831367A2 (fr) | 2007-09-12 |
WO2006061418A2 (fr) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
WO2007090569A8 (fr) | Composition sanguine conditionnée et son procédé de préparation | |
TN2011000415A1 (en) | Pharmaceutical composition comprising a sglt2 inhibitor a dpp-i v inhibitor and optionally a further antidiabetic agent and uses thereof | |
WO2008011363A3 (fr) | Compositions contenant de la quercétine | |
WO2009050506A3 (fr) | Combinaison 059 | |
WO2005077093A3 (fr) | Fabrication d'enzymes lysosomales hautement phosphorylees et utilisations associees | |
MY161472A (en) | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia | |
WO2007044950A3 (fr) | Formes cristallines de docetaxel et leurs processus de preparation | |
WO2006099941A8 (fr) | 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments | |
WO2006008028A8 (fr) | Nouvelles 6-formyltetrahydropteridines, procede de production et utilisation de ces dernieres comme medicaments, notamment contre le cancer | |
WO2007029249A3 (fr) | Oligoribonucleotides et leurs methodes d'utilisation dans le traitement des maladies cardio-vasculaires | |
WO2007146425A3 (fr) | Composés et procédés destinés au traitement prophylactique d'une anémie induite par une chimiothérapie | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
WO2006023452A3 (fr) | Analogues de la cyclosporine utilises pour le traitement de troubles immunoregulateurs et de maladies respiratoires | |
WO2011075606A3 (fr) | Variants de polypeptide hyperglycosylé et procédés d'utilisation | |
WO2008048121A3 (fr) | Composés et compositions | |
UA86399C2 (ru) | Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза | |
WO2005092878A3 (fr) | Analogues de schweinfurthines | |
WO2010072770A3 (fr) | Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial | |
WO2006019978A3 (fr) | Compositions et procedes pour le diagnostic et le traitement d'epilepsie | |
WO2008118792A3 (fr) | Lymphocytes t gamma delta et procédés de traitement de problèmes liés à l'interleukine-17 | |
WO2006061418A3 (fr) | Procedes et agents de traitement d'etats se caracterisant par une hyperproduction/hypersecretion de mucus | |
WO2008066770A3 (fr) | Composés activateurs de l'ace2 et procédés d'utilisation de ceux-ci | |
WO2005009361A3 (fr) | Methode de traitement a l'argatroban pour des patients souffrant de thrombocytopenie induite par l'heparine | |
WO2005107464A3 (fr) | Composes et compositions utilises en tant qu'inhibiteurs de la cathepsine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005816225 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005816225 Country of ref document: EP |